

PG3602USW

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Campbell et al.

Serial No.: 09/830,836 Group Art Unit: 1625

File Date: May 1, 2001 Examiner: S.E. Perlinger

For: Pyrazolopyridine Derivatives as Selective COX-2 Inhibitors

Director of the U.S. Patent and Trademark Office  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants respectfully request the Examiner take notice of the following copending patent applications. The U.S. serial numbers correspond to the WIPO publications as indicated in the chart below. The WIPO publications are also submitted on form 1449 attached to this Information Disclosure Statement.

Pub No.	USSN
WO99/12930	10/974893
WO03/077920	10/506,934
WO00/26216	09/830,836
WO02/18374	10/362745
" "	11/165073
WO02/096886	10/477546
WO02/096427	10/477819
" "	11/119653
WO03/14091	10/486,001
WO04/018452	10/524462
WO02/096885	10/477547
" "	11/110118
WO04/048344	10/535806
WO04/024691	10/527799
WO01/56573	10/786423

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

Copies of the references are enclosed: Ref. 27-87  
 Copies of the references were submitted in parent application \_\_\_\_\_ (37 CFR 1.98(d))

A copy of the International Search Report which issued on International Application No. \_\_\_\_\_ is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

A.  The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action or after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

B.  The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:

- (1) a final action under § 1.113 or
- (2) a notice of allowance under § 1.311, whichever occurs first.

Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

C.  The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).

The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.

Please charge any required fees to Deposit Account No.07-1392.

A duplicate copy of this paper is attached.

Respectfully Submitted,

  
J. Scott Young  
Registration No. 45,582

Date: August 17, 2006  
GlaxoSmithKline  
Corporate Intellectual Property  
5 Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Telephone: (919) 483-8160  
Facsimile: (919) 483-7988

<b>FORM PTO-1449</b> <b>INFORMATION DISCLOSURE STATEMENT</b>				ATTORNEY DOCKET NO.	SERIAL NO.	
				PG3602USW	09/830,836	
				APPLICANT: Campbell et al.		
				FILING DATE:	GROUP	
				May 1, 2001	1625	

**U.S. PATENT DOCUMENTS**

Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date if Appropriate
	1	2003/0018023	Jan. 23, 2003	Pinto et al.			
	2	2003/0013717	Jan. 16, 2003	Mangel et al.			
	3	3,149,109	Sept. 15, 1964	Neustaedter et al.			
	4	3,592,895	July 13, 1971	Hepworth et al.			
	5	5,474,995	Dec. 12, 1995	Ducharme et al.			
	6	5,760,068	June 2, 1998	Talley et al.			
	7	5,849,758	Dec. 15, 1998	Kleemann et al.			
	8	5,972,842	Oct. 26, 1999	Maier et al.			
	9	5,972,986	Oct. 26, 1999	Seibert et al.			
	10	5,985,886	Nov. 16, 1999	Elliott et al.			
	11	6,020,343	Feb. 1, 2000	Belley et al.			
	12	6,121,202	Sept. 19, 2000	Karp et al.			
	13	6,153,619	Nov. 28, 2000	Wood et al.			
	14	6,248,892	June 19, 2001	Noerenberg et al.			
	15	6,306,866	Oct. 23, 2001	Wood et al.			
	16	6,313,072	Nov. 6, 2001	Scheiblich et al.			
	17	6,355,799	Mar. 12, 2002	Gupta et al.			
	18	6,451,794	Sept. 17, 2002	Beswick et al.			
	19	6,498,166	Dec. 24, 2002	Campbell et al.			
	20	6,756,498	June 29, 2004	Fitzgerald et al.			
	21	6,759,413	July 6, 2004	Mangel et al.			
	22	6,780,869	Aug. 24, 2004	Green et al.			
	23	6,780,870 B2	Aug. 24, 2004	Carter et al.			
	24	6,803,463	Oct. 12, 2004	Mathews et al.			
	25	6,831,097	Dec. 14, 2004	Beswick et al.			
	26	6,861,249	Mar. 1, 2005	Kent			

Continue on page 2

**FOREIGN PATENT DOCUMENTS**

		Document Number	Publication Date	Country	Class	Subclass	Translation Yes   No
	27	DE 19909541	Mar. 4, 1999	GERMANY			Abstract only
	28	DE 19651099	June 10, 1998	GERMANY			
	29	DE 19708928	Sept. 10, 1998	GERMANY			
	30	DE 19831246	Jan. 1, 2000	GERMANY			
	31	EP 0723960	July 31, 1996	EUROPE			
	32	EP 0820996	Jan. 28, 1998	EUROPE			
	33	JP 09241161	Sept. 16, 1997	JAPAN			
	34	JP 2000026421	Jan. 25, 2000	JAPAN			
	35	JP 2001081074	Mar. 27, 2001	JAPAN			
	36	JP 2001252044	Nov. 22, 1999	JAPAN			
	37	JP 9241161	Sept. 16, 1997	JAPAN			Abstract only
	38	WO 96/07641	Mar. 14, 1996	WIPO			Abstract only
	39	WO 96/24585	Aug. 15, 1996	WIPO			

Continue on page 2

**OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)**

Continue on page

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.	

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO. PG3602USW	SERIAL NO. 09/830,836
				APPLICANT: Campbell et al.	
				FILING DATE: May 1, 2001	GROUP 1625

## U.S. PATENT DOCUMENTS

Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
-------------------	--	---------------	------------	------	-------	----------	----------------------------

Continue on page

## FOREIGN PATENT DOCUMENTS

		Document Number	Publication Date	Country	Class	Subclass	Translation Yes   No
40		WO 96/41625	Dec. 27, 1996	WIPO			
41		WO 96/41645	Dec. 27, 1996	WIPO			
42		WO 97/38996	Oct. 23, 1997	WIPO			
43		WO 98/03484	Jan. 29, 1998	WIPO			
44		WO 98/16227	Apr. 23, 1998	WIPO			
45		WO 98/24782	June 11, 1998	WIPO			
46		WO 99/01439	Jan. 14, 1999	WIPO			
47		WO 99/12930	Mar. 18, 1999	WIPO			
48		WO 99/21837	May 6, 1999	WIPO			
49		WO 99/55668	April 11, 1999	WIPO			X Abstract
50		WO 00/26216	May 11, 2000	WIPO			
51		WO 00/47553	Aug. 17, 2000	WIPO			
52		WO 00/52008	Sept. 8, 2000	WIPO			
53		WO 01/38311	May 31, 2001	WIPO			
54		WO 01/45703	June 28, 2001	WIPO			
55		WO 01/46194	June 28, 2001	WIPO			
56		WO 01/41760	June 14, 2001	WIPO			
57		WO 01/56573	Aug. 9, 2001	WIPO			
58		WO 01/58881	Aug. 16, 2001	WIPO			
59		WO 01/62233	Aug. 30, 2001	WIPO			
60		WO 01/83479	Nov. 8, 2001	WIPO			
61		WO 02/00647	Jan. 3, 2002	WIPO			
62		WO 02/00655	Jan. 3, 2002	WIPO			
63		WO 02/18374	Mar. 7, 2002	WIPO			
64		WO 02/44137	June 6, 2002	WIPO			X Abstract
65		WO 02/55484	July 18, 2002	WIPO			X Abstract
66		WO 02/59122	Aug. 1, 2002	WIPO			
67		WO 02/96427	Dec. 5, 2002	WIPO			
68		WO 02/96885	Dec. 5, 2002	WIPO			
69		WO 02/96886	Dec. 5, 2002	WIPO			
70		WO 02/100838	Dec. 19, 2002	WIPO			
71		WO 03/04472	Jan. 16, 2003	WIPO			
72		WO 03/14091	Feb. 20, 2003	WIPO			
73		WO 03/14092	Feb. 20, 2003	WIPO			
74		WO 03/22219	Mar. 20, 2003	WIPO			
75		WO 03/77920	Sept. 25, 2003	WIPO			

Continue on page 3

## OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

Continue on page

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO. PG3602USW	SERIAL NO. 09/830,836		
				APPLICANT: Campbell et al.			
				FILING DATE: May 1, 2001	GROUP 1625		
U.S. PATENT DOCUMENTS							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
Continue on page							
FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes   No
76	WO 04/18452	Mar. 4, 2003	WIPO				
77	WO 04/24691	Mar. 25, 2004	WIPO				
78	WO 04/48344	June 10, 2004	WIPO				
79	WO 05/16924	Feb. 24, 2005	WIPO				
Continue on page							
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
80	Casenova, B., et al. "A Critical Review of the current Pathogenesis of Multiple Sclerosis and Possible Future Trends." Pub Mcd Abstract 9Rev. Neurol. 28(9), May 1999, pgs. 909-915.						
81	Damasio, A.R., et al. Alzheimer's Disease and Related Dementias, Cecil Textbook of Medicine, Vol. 2, pp. 1992-1996, 1996.						
82	Douglas, R.G., Jr. "Introduction to Viral Diseases: Cecil Textbook of Medicine, 20 <sup>th</sup> Edition, Vol. 2, pp. 1739-1747, 1996.						
83	Preston, J.W., et al. Rationalizing Cyclooxygenase (COX) Inhibition for Maximal Efficacy and Minimal Adverse Events + Abstract, Am. J. Med. 107(6A):78S-88S; Discussion 89S, December 1999.						
84	Layzer, R.B., et al. Degenerative Diseases of the Nervous System, Cecil Textbook of Medicine, 20 <sup>th</sup> Edition, Vol. 2, pp. 2050-2057, 1996.						
85	Naesdal, J. et al. "Gastro-Duodenal Protection in an Era of Cyclo-Oxygenase-2-Selective Nonsteroidal Anti-inflammatory Drugs." PubMed Abstract, Eur J Gastroenterol Hepatol, 13(12):1401-1406, December 2001.						
86	Simone, JV., et al. "Oncology: Introduction, Cecil Textbook of Medicine, 20 <sup>th</sup> Edition, Vol. 1, pp. 1004-10, 1996.						
87	Stanghellini, V., et al. "Risk Indicators of Delayed Gastric Emptying of Solids in Patients With Functional Dyspepsia." Gastroenterology, 110(40, 1996, pgs 1036-1042.						
Continue on page							
EXAMINER					DATE CONSIDERED		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							